Italy Opens Antitrust Probe into Biogen Over Alleged Dominance in MS Drug Market
BIIB sits 60% above its 52-week low of $121.05.
Summary
Italy's antitrust regulator has opened an investigation into Biogen and its Italian subsidiary, alleging abuse of a dominant position in the multiple sclerosis drug market. The probe focuses on claims that Biogen sought to exclude rival Sandoz from offering natalizumab-based drugs. This development introduces significant regulatory risk for Biogen, potentially leading to fines, market restrictions, or reputational damage in a crucial therapeutic area.
At the time of this announcement, BIIB was trading at $193.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.5B. The 52-week trading range was $121.05 to $205.97. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.